 Alterity Therapeutics Ltd NASDAQ:ATHE ASX:ATH surged 58 in pre-market trade in New York as the company announced the award of a new patent, which advances its journey towards finding a clinical candidate to treat major neurodegenerative diseases, such as Alzheimers and Parkinsons. The company has bene granted a new composition of matter patent by the United States Patent and Trademark Office USPTO. 